Global /China /Industrials /Specialty Business Services /600645
chevron_leftBack
Vcanbio Cell & Gene Engineering Corp., Ltd. logo

Vcanbio Cell & Gene Engineering Corp., Ltd.

600645
SSE: 600645 Delayed
25.87CNY -2.2%
3.82 USD
As of 6 June 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. has a market cap of $1.74B USD, ranking #7715 globally and #1947 in China. It ranks #1655 in the Industrials sector, and #133 in the Specialty Business Services industry.
Global Rank
7715
Country Rank
1947
Sector Rank
1655
Industry Rank
133
Key Stats
Market Cap
$1.74BUSD
11.79B CNY
Enterprise Value
$1.5BUSD
10.18B CNY
Revenue (TTM)
$209.99MUSD
1.42B CNY
EBITDA (TTM)
$50.78MUSD
343.77M CNY
Net Income (TTM)
$16.26MUSD
110.05M CNY
EBITDA Margin
24%
Profit Margin
7.7%
PE Ratio
108.1
PS Ratio
8.3
PB Ratio
3.1
EV/EBITDA
29.4
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Hongqi Wang open_in_new
Employees
2,014
Founded
1992
Website
vcanbio.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.2% -6.1% -17% 1.2% 11% 21%

News

Loading...

Markets

Exchange Ticker Price
Shanghai Stock Exchange
MIC: XSHG
PRIMARY
600645
中源协和细胞基因工程股份有限公司 Class A
ISIN: CNE000000545
Shares Out.:
455.095M1 Shares Float: 334.0M2
TV:
SA:
YF:
GF:
BA:
MS:
25.87 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Vcanbio Cell & Gene Engineering Corp., Ltd.

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, it is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and synthetic agents; and in vitro diagnostic reagents and medical devices. The company was founded in 1992 and is based in Tianjin, the People’s Republic of China.

Similar Companies

Industry: Specialty Business Services (China)
Name
Market Cap diff.
PE
$9.42B
73.79B HKD
441%
47.0
$8.77B
59.36B CNY
403%
296.1
$6.6B
279%
11.8
$6.25B
42.34B CNY
259%
480.6
$4.62B
31.29B CNY
165%
128.4
$4.6B
31.16B CNY
164%
163.3
Industry: Specialty Business Services (Global)
Name
Market Cap diff.
PE
SHOP
$158.14B
9K%
129.8
VSURE
$133.34B
114.8B EUR
8K%
-
CTAS
$69.6B
4K%
36.8
REL
$63.91B
47.6B GBP
4K%
23.9
PYPL
$45.83B
3K%
9.4
$41.8B
56.91B CAD
2K%
-
chevron_leftBack